Meet the Proteona team at the CAR-TCR Sumit Asia in Shanghai, China
Innovative combined genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications
The Proteona team will attend the CAR-TCR Summit Asia from the 19th to the 20th June 2019, taking place in Shanghai, China. The CAR-TCR Summit Asia focusses on clinical application of cell immunotherapies, especially CAR T and TCR therapies. It covers important topics such as new technologies to improve CAR T manufacturing process.
The team will be available during the conference to share about the new ESCAPETM CAR T platform. This new product will be available for comprehensive characterization of CAR T immunotherapeutics, and can be integrated into all stages of CAR T therapy from quality control to analysing patient follow-up samples.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.